Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 20, 2026Oncology Research and Treatment

Real world experiences in the treatment of immune thrombocytopenia over a two-year period

View Full Paper
Ask AI
Bookmark
Share

Authors

GCGeothy ChakupurakalKVKarl VerpoortFKFlorian Kaiser

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows effective outpatient management of immune thrombocytopenia, highlighting treatment outcomes.

Key Points

  • This study aims to analyze real-world outcomes of outpatient care for patients with immune thrombocytopenia (ITP).
  • Retrospective analysis of 91 patients diagnosed with primary ITP from 01/2020 to 12/2021.
  • Patients' treatment histories and platelet counts were analyzed, focusing on therapies used and outcomes obtained.
  • Data included details on therapy lines, types of treatments, and results like complete response (CR) and partial response (R).
  • At diagnosis, the mean age of patients was 55 years, with an initial mean platelet count of 26 g/l.
  • The primary treatment involved corticosteroids (56% of patients), and overall, patients had varied treatment responses: 39% achieved CR, 18% R, and 43% NR.
  • No grade III bleeding complications were reported during treatment, indicating safe management of ITP in an outpatient setting.

Cite This Study

Chakupurakal et al. (2026) studied this question.

synapsesocial.com/papers/6a363040db0793dc1a5377cahttps://doi.org/10.1159/000553069
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Retrospective Evaluation of Survival and Prognostic Factors in Immune Thrombocytopenia: A Single-Center and Cross-Sectional Study2024 · 1 citations
  2. 2MAINTENANCE LOW-DOSE CORTICOSTEROID THERAPY IN PATIENTS WITH CHRONIC ITP: SINGLE CENTER RESULTS2024
  3. 3Clinical characteristics, management strategies, and outcomes of pediatric immune thrombocytopenic purpura: a five-year single-center experience.2026
  4. 4A Single-Center Experience of Immune Thrombocytopenic Purpura: Disease Characteristics, Treatment Options, Response to Treatment, and Side Effects2025 · 1 citations
  5. 5Assessment of Clinical Course and Treatment Responses in Our Patients with Immune Thrombocytopenia2026